PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

被引：3
|
作者：
Raben, D. [1 ]
Faivre-Finn, C. [2 ]
Spigel, D. [3 ]
Daniel, D. [3 ,4 ]
Villegas, A. [5 ]
Vincente, D. [6 ]
Hui, R. [7 ,8 ]
Carpeno, J. de Castro [9 ]
Murakami, S. [10 ]
Paz-Ares, L. [11 ,12 ]
Ozguroglu, M. [13 ]
Kurata, T. [14 ]
Chiappori, A. [15 ]
Lee, K. H. [16 ]
de Wit, M. [17 ]
Poole, L. [18 ]
Wadsworth, C. [19 ]
Dennis, P. A. [20 ]
Antonia, S. J. [15 ]
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Chattanooga, TN USA
[5] Canc Specialists North Florida, Jacksonville, FL USA
[6] Hosp Univ Virgen Macarena, Seville, Spain
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Univ Sydney, Sydney, NSW, Australia
[9] Hosp Univ La Paz, Madrid, Spain
[10] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[11] Univ Complutense, Hosp Univ Octubre 12, CiberOnc, Madrid, Spain
[12] CNIO, Madrid, Spain
[13] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey
[14] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[15] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[16] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[17] Vivantes Klinikum Neukoelln, Berlin, Germany
[18] AstraZeneca, Cambridge, England
[19] AstraZeneca, Alderley Pk, England
[20] AstraZeneca, Gaithersburg, MD USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 05期
关键词：
D O I：
10.1016/j.ijrobp.2018.08.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA10
引用
收藏
页码：1607 / 1608
页数：2
相关论文
共 50 条
  • [31] PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
    Vansteenkiste, J.
    Naidoo, J.
    Faivre-Finn, C.
    Ozguroglu, M.
    Villegas, A.
    Daniel, D.
    Murakami, S.
    Hui, R.
    Lee, K.
    Cho, B. C.
    Kubota, K.
    Poole, L.
    Wadsworth, C.
    Dennis, P.
    Antonia, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S370 - S371
  • [32] Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
    Hussain, Salman
    Klugarova, Jitka
    Klugar, Miloslav
    LUNG CANCER, 2022, 170 : 11 - 19
  • [33] Safety and Efficacy Results of Durvalumab following Sequential Chemoradiotherapy (sCRT) in Unresectable Stage III NSCLC (PACIFIC 6)
    Heilmann, M.
    Garassino, M. C.
    Mazieres, J.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L.
    Mansy, T.
    Cortinovis, D.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. G.
    Velarde, L. E. C.
    Bernabe, R.
    Paz-Ares, L.
    Perez, Diaz, I
    Trunova, N.
    Foroutanpour, K.
    Faivre-Finn, C.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 97 - 98
  • [34] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
    Park, Cheol-Kyu
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Jeong, Won Gi
    Lee, Jeong Yeop
    Lee, Jae Cheol
    Choi, Chang Min
    Ji, Wonjun
    Song, Si Yeol
    Choi, Juwhan
    Lee, Sung Yong
    Kim, Hakyoung
    Lee, Shin Yup
    Park, Jongmoo
    Yoon, Seong Hoon
    Joo, Ji Hyeon
    Oh, In-Jae
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054
  • [35] Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial
    Zhao, Binghao
    Li, Huanzhang
    Wu, Jiaming
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01)
  • [36] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Girard, N.
    Mornex, F.
    Christoph, D. C.
    Fietkau, R.
    Filippi, A. R.
    Field, J.
    Garrido Lopez, P.
    McDonald, F.
    Peters, S.
    Klein, A. B.
    Licour, M.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Christoph, D. C.
    Behringer, D.
    Emde, T. O.
    Goekkurt, E.
    Laack, E.
    Mueller-Huesmann, H.
    Schuett, P.
    Schumann, C.
    Seese, B.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
  • [38] Impact of chemoradiotherapy on the survival of patients with stage III NSCLC
    Basto, R.
    Correia Magalhaes, J.
    de Sousa, M. J. P.
    Monteiro, J. C.
    Domingues, I.
    Jesus, E.
    Sousa, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S743 - S743
  • [39] Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy
    Taugner, Julian
    Kaesmann, Lukas
    Eze, Chukwuka
    Dantes, Maurice
    Roengvoraphoj, Olarn
    Gennen, Kathrin
    Karin, Monika
    Petruknov, Oleg
    Tufman, Amanda
    Belka, Claus
    Manapov, Farkhad
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 593 - 604
  • [40] Overall Survival by PD-L1 Status in Stage III NSCLC Following Implementation of Durvalumab: The Real-World Application of PACIFIC
    Kuang, S.
    Liu, M.
    Ho, C.
    Berthelet, E.
    Laskin, J.
    Sun, S.
    Zhang, T.
    Melosky, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S365 - S365
12345